Image de couverture de livre

Letter: Allostatic load—A potential key in the development of inflammatory bowel disease

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Maryam Kharal, Muhammad Hassan Shahbaz, Muhammad Salman Nadeem, Sana Shahbaz
Format:	Artículo Open Access
Publié:	Wiley 2024
Sujets:	Alimentary Pharmacology & Therapeutics
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Allostatic load increases the incidence and risk of adverse prognosis in inflammatory bowel disease
par: Jianhui Zhao, et autres
Publié: (2024)

Letter: Thioguanine, an under‐utilised option in inflammatory bowel disease? Authors' reply
par: Abhinav Vasudevan, et autres
Publié: (2024)

Letter: Light in the lumen—The expanding role of intestinal ultrasound for functional symptoms in inflammatory bowel disease
par: R. M. Mathias, et autres
Publié: (2024)

Letter: Diet‐microbiome interactions in inflammatory bowel disease—Navigating towards individualised dietary strategies
par: Iris Barth, et autres
Publié: (2024)

Letter: Microbial manipulation for primary sclerosing cholangitis‐associated inflammatory bowel disease—hope on the horizon
par: D. Bogatic, et autres
Publié: (2024)

Letter: Lubiprostone—A Novel Therapeutic Avenue for Gastrointestinal Complications in MASLD
par: Hassan Javed, et autres
Publié: (2025)

Letter: The Prognostic Role of IGF‐1 in Chronic Liver Disease
par: Muhammad Osama, et autres
Publié: (2024)

Review article: Prevention of inflammatory bowel disease—The path forward
par: Sérgio Bronze, et autres
Publié: (2024)

Editorial: GLP‐1 receptor agonists in inflammatory bowel disease—Is it time?
par: Konstantinos Arvanitakis, et autres
Publié: (2024)

Review article: Novel therapies in inflammatory bowel disease – An update for clinicians
par: Nurulamin M. Noor, et autres
Publié: (2024)

Meta‐analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease
par: Tsz Hong Yiu, et autres
Publié: (2024)

Review article: Evidence‐based dietary management of inflammatory bowel disease
par: Peter R. Gibson, et autres
Publié: (2024)

Editorial: Treatments for inflammatory bowel disease across the age‐spectrum—Are they the same?
par: Agnes Hiu Yan Ho, et autres
Publié: (2024)

Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis‐associated inflammatory bowel disease (PSC‐IBD): A matched analysis from the Paediatric PSC Consortium
par: Amanda Ricciuto, et autres
Publié: (2024)

Letter: Allostatic Load and Adverse Prognosis in Inflammatory Bowel Disease—Need More Evidence. Authors' Reply
par: Jianhui Zhao, et autres
Publié: (2024)

Systematic review: Methotrexate—A poorly understood and underused medication in inflammatory bowel disease
par: Léa Sequier, et autres
Publié: (2024)

Editorial: Towards optimal thiopurine therapy for inflammatory bowel disease—authors' reply
par: Abhinav Vasudevan, et autres
Publié: (2024)

The contribution of dietary advanced glycation end‐products and genetic risk in the development of inflammatory bowel disease: a prospective cohort study
par: Fangyuan Jiang, et autres
Publié: (2024)

Review article: A practical approach to persistent gastrointestinal symptoms in inflammatory bowel disease in remission
par: Arta Aliu, et autres
Publié: (2024)

Review article: Optimisation of biologic (monoclonal antibody) therapeutic response in inflammatory bowel disease
par: Thanaboon Chaemsupaphan, et autres
Publié: (2024)

Letter: Irritable bowel syndrome and antibiotics
par: George F. Longstreth
Publié: (2024)

Impact of inflammatory bowel disease on the risk of acute coronary syndrome: A Swedish Nationwide Cohort Study
par: Carl Eriksson, et autres
Publié: (2024)

Review article: The role of the gut–brain axis in inflammatory bowel disease and its therapeutic implications
par: Christy Riggott, et autres
Publié: (2024)

Editorial: Allostatic Load and Inflammatory Bowel Disease
par: Jeli Mendoza, et autres
Publié: (2024)

Letter: Irritable bowel syndrome and antibiotics—Authors' reply
par: Kyle Staller, et autres
Publié: (2024)

Editorial: Is it time to include oral vancomycin in therapeutic guidelines for primary sclerosing cholangitis‐associated inflammatory bowel disease?
par: Ayesha Shah, et autres
Publié: (2024)

Editorial: Allostatic Load and Inflammatory Bowel Disease. Authors' Reply
par: Jianhui Zhao, et autres
Publié: (2024)

Use of glucagon‐like peptide‐1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease
par: Aakash Desai, et autres
Publié: (2024)

Letter: Unmasking the Risks—The Need for Robust Data on Baclofen in Cirrhotic Patients
par: Zainab Salman
Publié: (2026)

Application of clinical decision support tools for predicting outcomes with vedolizumab therapy in patients with inflammatory bowel disease: A KASID multicentre study
par: Kyuwon Kim, et autres
Publié: (2024)

Letter: Methodological Caveats in Zhang et al.–Gut Microbiota and Metabolism in Cirrhotic Portal Hypertension
par: Muhammad Talha Ghaffar
Publié: (2025)

Inflammatory bowel disease in 2024 and beyond
par: Richard B. Gearry, et autres
Publié: (2024)

Treatment of inflammatory bowel disease with steroid‐sparing medications is age‐dependent – Results from a Danish nationwide cohort study, 2000–2018
par: Rie Louise Møller Nordestgaard, et autres
Publié: (2024)

Letter on ‘Head‐to‐Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of MetALD Versus MASLD: A Prospective Study’
par: Muhammad Abubakr, et autres
Publié: (2025)

Letter on ‘Unveiling Drug‐Induced Autoimmune‐Like Hepatitis in Autoimmune Hepatitis Patients: A Multicenter Retrospective Study’
par: Muhammad Ibrahim Khalil, et autres
Publié: (2025)

Letter: Optimising public health policies to combat alcohol‐associated liver disease in youth—Addressing key methodological and regional challenges
par: Rui Zhang, et autres
Publié: (2024)

Performance of bowel preparation quality scales in patients with Crohn's disease
par: Virginia Solitano, et autres
Publié: (2024)

Letter: Early real‐world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease
par: Maryam Alahmad, et autres
Publié: (2024)

Letter: Crohn's Disease With Latent Tuberculosis Infection or Intestinal Tuberculosis: Rapid Discrimination by Targeted Next‐Generation Sequencing
par: Maryam Irshad, et autres
Publié: (2025)

Systematic review: Defining, diagnosing and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound
par: Cathy Lu, et autres
Publié: (2024)